EMA Authorised: Ozempic (semaglutide) — Novo Nordisk A/S

View source ↗

Summary

The EMA authorised Ozempic (semaglutide) from Novo Nordisk A/S for the treatment of diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• OZEMPIC (semaglutide)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus. MAH: Novo Nordisk A/S. Decision date: 26/03/2026